SAN DIEGO, May 22 /PRNewswire/ -- Victory Pharma, Inc. announced today
that Dr. Shawn A. Scranton has joined the Company as Vice President of
Scientific Operations. Dr. Scranton will report to Matthew Heck, President,
and will serve as a member of the Company's senior executive team.
"Victory is pleased to have attracted a person of Dr. Scranton's
caliber, and his strategic medical knowledge signals our focus on bringing
products to market and increased growth in sales," commented Mr. Heck. "As
we bring more pharmaceutical products through the pipeline, Dr. Scranton's
contributions will be extremely valuable." Dr. Scranton observed, "Victory
Pharma's proven management team and recent commercialization successes
combined with high potential products currently under development were the
key reasons I decided to join the Company."
Dr. Scranton brings over 15 years of drug development experience to
Victory Pharma. Most recently he was Senior Director of Translational
Medicine for Kalypsys, Inc., where he contributed to nonclinical,
regulatory, and clinical strategies that allowed for the successful opening
of NCE INDs, and conduct of subsequent Phase I clinical programs in
neuropathic pain and metabolic disease. Formerly, Dr. Scranton was Director
of Clinical Development and Program Director of the SDX101 program for
Salmedix, Inc., which was acquired by Cephalon, Inc. in 2005. Additionally,
Dr. Scranton has also held academic positions at University of the Pacific,
University of Houston, and Baylor College of Medicine.
Dr. Scranton will be based in the Company's corporate headquarters in
San Diego, California.
About Victory Pharma, Inc.
Victory Pharma, Inc. is a privately held, specialty pharmaceutical
company, headquartered in San Diego with sales and marketing operations in
Cary, NC, focused on acquiring and marketing pain and related products.
Victory markets its existing pain products through its physician based
field sales force. The Company is also developing several proprietary
products for treatment of chronic severe pain and commonly associated
opiate induced side effects. Its lead development product is currently near
completion of Phase II clinical testing in the United States. Further
information regarding Victory is available at http://www.VictoryPharma.com.
SOURCE Victory Pharma, Inc.